Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt IssuancesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibrx Biosciences (INBX) Change in Account Payables: 2023-2024

Historic Change in Account Payables for Inhibrx Biosciences (INBX) over the last 2 years, with Dec 2024 value amounting to $17.9 million.

  • Inhibrx Biosciences' Change in Account Payables fell 237.56% to -$1.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$5.6 million, marking a year-over-year decrease of 123.36%. This contributed to the annual value of $17.9 million for FY2024, which is 748.89% up from last year.
  • Per Inhibrx Biosciences' latest filing, its Change in Account Payables stood at $17.9 million for FY2024, which was up 748.89% from $2.1 million recorded in FY2023.
  • Over the past 5 years, Inhibrx Biosciences' Change in Account Payables peaked at $17.9 million during FY2024, and registered a low of $2.1 million during FY2023.
  • Over the past 2 years, Inhibrx Biosciences' median Change in Account Payables value was $10.0 million (recorded in 2023), while the average stood at $10.0 million.
  • Data for Inhibrx Biosciences' Change in Account Payables shows a peak YoY skyrocketed of 748.89% (in 2024) over the last 5 years.
  • Inhibrx Biosciences' Change in Account Payables (Yearly) stood at $2.1 million in 2023, then soared by 748.89% to $17.9 million in 2024.